Attached files

file filename
10-Q - FORM 10-Q - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838e10vq.htm
EX-32 - EXHIBIT 32 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv32.htm
EX-4.4 - EXHIBIT 4.4 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv4w4.htm
EX-4.1 - EXHIBIT 4.1 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv4w1.htm
EX-4.3 - EXHIBIT 4.3 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv4w3.htm
EX-4.2 - EXHIBIT 4.2 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv4w2.htm
EX-10.8 - EXHIBIT 10.8 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w8.htm
EX-10.4 - EXHIBIT 10.4 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w4.htm
EX-10.5 - EXHIBIT 10.5 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w5.htm
EX-10.6 - EXHIBIT 10.6 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w6.htm
EX-10.9 - EXHIBIT 10.9 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w9.htm
EX-10.2 - EXHIBIT 10.2 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w2.htm
EX-10.1 - EXHIBIT 10.1 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w1.htm
EX-21.1 - EXHIBIT 21.1 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv21w1.htm
EX-10.7 - EXHIBIT 10.7 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w7.htm
EX-31.1 - EXHIBIT 31.1 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv31w1.htm
EX-10.3 - EXHIBIT 10.3 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w3.htm
EX-31.2 - EXHIBIT 31.2 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv31w2.htm
EX-10.15 - EXHIBIT 10.15 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w15.htm
EX-10.16 - EXHIBIT 10.16 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w16.htm
EX-10.13 - EXHIBIT 10.13 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w13.htm
EX-10.14 - EXHIBIT 10.14 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w14.htm
EX-10.18 - EXHIBIT 10.18 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w18.htm
EX-10.20 - EXHIBIT 10.20 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w20.htm
EX-10.17 - EXHIBIT 10.17 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w17.htm
EX-10.10 - EXHIBIT 10.10 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w10.htm
EX-3.1 - EXHIBIT 3.1 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv3w1.htm
EX-10.11 - EXHIBIT 10.11 - ROBERTSON GLOBAL HEALTH SOLUTIONS CORPc04838exv10w11.htm
Exhibit 10.19
International Countries Addendum to Robertson Technologies
Licensing, Agreement with Companies On Text, L.L.C. Licensing
Agreement
As of 04/28/2010, the contract entitled Robertson Technologies Licensing, LLC And Companies On Text, L.L.C., a contracted distributor of Aversien Science, LLC Licensing Agreement between Robertson Technologies Licensing, LLC and Companies On Text, L.L.C. will be supplemented as follows:
I. DISTRIBUTION RIGHTS will be added as follows:
Licensee has the right to sell Licensor solutions. Licensor has an inherit right to make sales through its own organization and other contractual relationships as well. However, for the purpose of distribution this will consist of direct to consumer markets in United Arab Emirates, Australia, China, Saudi Arabia with Exclusivity, WHERE Licensee is granted exclusivity in this space for a period of three (3) years provided the performance measures listed in XVIII are met. If a sale is made by any other party in these markets utilizing the concept developed for these markets, the sale must flow thru Licensee. Licensee will have the responsibility to facilitate the implementation of the sales process as it does for its own direct customer. Licensee will have the right to generate its mark up or profit margin for the customers brought by other parties, provided the price point is consistent with the model developed and agreed upon.
II. PERFORMANCE MEASURES
Licensee Measures
Year 1 — Licensee is required to purchase a minimum of five million (5,000,000) licenses from the Licensor. Licensee is granted a program implementation period of six (6) months and program execution period of twelve (12) months for a total of eighteen (18) months.
Year 2 — Licensee is required to purchase a minimum of seven million (7,000,000) licenses from the Licensor.
Year 3 — Licensee is required to purchase a minimum of nine million (9,000,000) licenses from the Licensor.
Licensor Measures
Year 1 — Licensor is required to be able to provision five million (5,000,000) licenses.
Year 2 — Licensor is required to be able to provision seven million (7,000,000) licenses.
Year 3 — Licensor is required to be able to provision nine million (9,000,000) licenses.
At the end of the first 12 months licensor will review exclusivity performance and if required take corrective action to get back on track.

 

 


 

III. SUPPORT Licensee shall receive the support of Licensor in its efforts to market Licensor products/licenses. Aversien Science shall facilitate the support services on behalf of Licensor. This includes making arrangements, where deemed appropriate for appearances at key events, attend key meetings, endorsements (letters, video, audio, media’s, etc.). Licensor shall support its business technology systems, deliverance of technology to consumer sector, and expertise in handling technical questions. Licensor through Aversien Science shall provide training on its products/licenses to Licensee and its agents/contractors. Once trained, Licensee may become a technical implementation partner with Licensor with the capabilities of training all future contractors, agents, distribution outlets, etc. This will be reviewed and is at the sole discretion of Aversien Science and Licensor.
Any costs incurred by Licensee in the marketing and distribution of the Licensor Technology are the sole responsibility of Licensee. Such costs include, but are not limited to, travel, entertainment, printing and marketing, etc. Licensee may use certain logos and corporate partner names in marketing materials and sales presentations as agreed upon. All marketing materials developed for the purpose of selling to customers must be pre-approved by Aversien Science, L.L.C. and Licensor before use. Licensor, Aversien Science, and Licensee agree to establish a marketing material response process of seven (7) days or less for material approval. All press related material will be coordinated and approved by Licensor and Aversien Science. Licenses purchased by Licensee are one year renewable licenses and the end user has unlimited use of the general license for one full year from time of purchase, at which time a payment is due to continue use of the license.
IV. PAYMENTS.
  1.   License Fees. In consideration for the license and other rights granted to Licensee, Licensee will pay Licensor license fees as follows:
  a.   Eight Dollars ($8.00) per license distributed through licensee. License is for a one (1) year usage and is renewable annually at the same Eight Dollar ($8.00) rate. However, Licensor and Aversien Science reserve the right to adjust pricing according to business and market conditions at the end of three-year contract from date of contract execution.
  2.   Application of License Fees. All License fees are paid in full at the time of purchase.
  3.   Exclusivity Rights Market Fees. The acquisition cost to the Licensee for the exclusive rights to distribute Licensor technology in the above-mentioned markets is One Million Dollars ($1,000,000) USD, and the pre purchase of three hundred seventy-five thousand (375,000) licenses at Eight Dollars ($8.00) per license, payable on or before 30 days following execution of this Agreement.
  4.   Platform Setup Fees. Platform Setup fees of One Million Two Hundred Fifty Dollars ($1,250,000) USD are payable to the Licensor payable upon execution of this Agreement. This will include one (1) major language per country.

 

 


 

[SIGNATURE PAGE]
This Amendment to the Agreement is entered into by the parties as of the Effective Date.
DATE: May 10, 2010
Technology Provider:
Robertson Technologies Licensing, LLC
         
By:
  /s/ Joel C. Robertson
 
   
 
  Dr. Joel Robertson    
 
  CEO    
 
       
Companies On Text:
LICENSEE
   
 
       
By:
  /s/ Michael Brady
 
   
 
  Michael Brady    
 
  CEO